Achieving Optimal Outcomes in Patients with Narcolepsy

This activity is part of a series


Richard K. Bogan, MD, FCCP, FAASM
Associate Clinical Professor
University of South Carolina Medical School, Columbia, SC
Medical University of South Carolina, Charleston, SC
Principal, Bogan Sleep Consultants, LLC
Columbia, SC
Richard K. Bogan, MD, FCCP, FAASM

Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, S.C.

Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine and Pulmonary Diseases.

Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia and circadian rhythm abnormality.

Julie Flygare, JD
President & CEO, Project Sleep, Los Angeles, CA
Author, Wide Awake and Dreaming: A Memoir of Narcolepsy
Julie Flygare, JD

Julie Flygare, JD, is a leading ambassador for narcolepsy and sleep, and a strong advocate for patient-centered research. She is an accomplished speaker, Stanford Medicine X ePatient Scholar, and the award-winning author of Wide Awake and Dreaming: A Memoir of Narcolepsy. As President & CEO of Project Sleep, Julie leads the organization’s patient- driven advocacy, awareness, and education programs. For over a decade, she has fostered a variety of successful collaborations including bringing together 29 patient advocacy organizations to co-lead World Narcolepsy Day and launching the Sleep Advocacy Forum to elevate the sleep community’s profile on the national policy stage. Julie has lectured at numerous professional meetings across the U.S. and keynoted conferences in Ireland, Italy, Sweden, Australia, and the United Kingdom. She has co-authored papers in peer-reviewed publications and authored a chapter in a narcolepsy clinical textbook. Julie received her BA from Brown University and her JD from Boston College Law School focusing on health law and rare disease drug development. Most recently, on March 20th, 2022, she delivered a TEDx talk at San Diego State University to open people’s eyes to the importance of sleep health and sleep disorders.

Michael J. Thorpy, MD
Professor of Neurology, Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center, Department of Neurology
Montefiore Medical Center, Bronx, NY
President, New York State Society of Sleep Medicine
Past President, Sleep Section of the Academy of Neurology
Michael J. Thorpy, MD

Dr. Thorpy is a Professor of Neurology at Albert Einstein College of Medicine and Director of the Sleep-Wake Disorders Center in the Department of Neurology at Montefiore Medical Center, both in New York. In addition to treating patients with sleep disorders, he conducts research in narcolepsy, insomnia and sleep apnea. He is President of the New York State Society of Sleep Medicine, Past President of the Sleep Section of the Academy of Neurology, and Past Secretary of the National Sleep Foundation. In 1993 Dr. Thorpy received the Nathaniel Kleitman Award from the American Academy of Sleep Medicine, one of the field’s highest honors, and in 2012 he received the Lifetime Achievement Award from the National Sleep Foundation.

Born in New Zealand, Dr. Thorpy earned his medical degree from the University of Otago Medical School. After receiving postgraduate training in Dunedin, New Zealand; Bombay, India; and London, England, he completed his residency in neurology at the State University of New York in Syracuse and a neuroendocrinology fellowship at Albert Einstein College of Medicine and Montefiore Medical Center. Dr. Thorpy is board certified in sleep medicine.

He has published extensively on narcolepsy, insomnia, and sleep disorders. He chaired the first International Classification of Sleep Disorders and has published more than 250 peer-reviewed articles and chapters, including publications in journals such as The New England Journal of Medicine. His numerous books include “The Encyclopedia of Sleep and Sleep Disorders“, ‘ ‘Parasomnias’ (2010), ‘Sleepiness” (2011), ‘Neuroimaging of Sleep and Sleep Disorders’ (2012), ‘Genetics of Sleep and Sleep Disorders’ (2013), ‘Narcolepsy: a clinical guide’ (2016),  and ‘SleepMultiMedia, a computerized textbook of sleep medicine’ (v12).0 (2023)

Dr. Thorpy has given more than 100 television, radio, and print interviews on sleep disorders.

Terri E. Weaver, PhD, RN, FAAN, ATSF, FAASM
Professor Emerita of Biobehavioral Nursing Science, College of Nursing University of Illinois Chicago, Chicago, IL
Professor Emerita of Nursing, University of Pennsylvania, Philadelphia, PA
Terri E. Weaver, PhD, RN, FAAN, ATSF, FAASM

Terri Weaver is dean emerita at the University of Illinois Chicago College of Nursing. She is recognized nationally and internationally for her research on the effect of daytime sleepiness on daily behaviors and assessment of treatment outcomes. Her research career has been honored with many accolades, including induction into the Sigma Theta Tau International Nurse Researcher Hall of Fame. Distinguished as a leader in nursing education, Dr. Weaver was also elected in 2017 to a two-year term on the board of directors of the American Association of Colleges of Nursing. In 2018, she was named to the first class of fellows of the American Thoracic Society.

As a researcher, Dr. Weaver has been supported with funding from the National Institutes of Health, the National Heart, Lung and Blood Institute and the National Institute of Nursing Research. She has produced two notable disease-specific functional status measures, one for chronic pulmonary disorders and the other for sleep disorders. The latter, the Functional Outcomes of Sleep Questionnaire, has become the gold standard for the evaluation of evaluating the impact of treatments for sleep disorders to improve quality of life and; it has been translated into 51 languages and used internationally in clinical trials.

Dr. Weaver earned her BSN at the University of Pittsburgh and her MSN and PhD from the University of Pennsylvania. She is a fellow of the American Academy of Nursing, where she previously served as a member of its Board of Directors. Additionally, she is the Training and Education Chair for the World Federation of Sleep Research & Sleep Medicine Societies and the former chair of the national board of directors of the American Lung Association. She has also held leadership positions in the American Thoracic Society, the American Academy of Sleep Medicine and the Sleep Research Society.

Statement of Need

Narcolepsy is a devastating, neurological condition characterized by excessive daytime sleepiness (EDS), the most common presenting symptom, as well as cataplexy, hypnagogic hallucinations, and sleep paralysis. Though recent practice guidelines have been released, these guidelines do not include recent U.S. Food and Drug Administration (FDA) approvals with strategies to lower sodium, which may be an ideal treatment option in patients with cardiovascular (CV) comorbidities or risk factors. As patients with narcolepsy often experience residual EDS despite traditional treatment, it is imperative that health care professionals (HCPs) possess the knowledge to identify EDS and skills to integrate effective novel therapies to achieve sustained benefits to optimize patient outcomes.

Join Drs. Bogan, Thorpy, and Weaver for an OnDemand symposium as they discuss evidence-based strategies to reduce EDS and cataplexy, among other symptoms, and restore quality of life and functioning in patients with narcolepsy.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Explain the patient’s journey with narcolepsy, including the extensive impact of work, psychosocial, and daily functioning to overall health.
  • Analyze the practice implications using evidence-based screening tools and diagnostic criteria to accelerate the early, accurate diagnosis of narcolepsy.
  • Integrate strategies to mitigate CV risk associated with narcolepsy in treatment decision-making.
  • Implement evidence-based strategies for the initiation and/or switching of therapies to improve and sustain patient QoL and psychosocial and work functioning.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in sleep medicine, psychiatry, neurology, pulmonology and/or primary care

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.0 contact hour.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
UAN: JA0007185-0000-22-066-H01-P

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bogan reports the following financial relationships: Consultant: Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. Grants: Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. Speakers Bureau: Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.

Ms. Flygare reports the following financial relationships: Consultant: Orexia Therapeutics and Takeda Pharmaceutical Company Limited

Dr. Thorpy reports the following financial relationships: Advisory Board and Consultant: Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Limited; Takeda Pharmaceutical Company Limited; and XWPharma

Dr. Weaver reports the following financial relationships: Advisory Board: Idorsia Pharmaceuticals Alliance for Sleep; Consultant: Bayer and Eli Lilly and Company; Other Financial Support: Axsome Therapeutics, Inc.; Bayer AG; Clinical Outcomes Solutions; Cook Medical; Eli Lilly and Company; Functional Outcomes of Sleep Questionnaire (FOSQ); Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; LivaNova PLC; Nyxoah; Philips Respironics; ResMed; ResMed Germany; RWS; Signant Health; Signifier Medical Technologies; Stratevi; Valis Biosciences Inc.; and Verily Life Sciences

The following peer reviewer and CME Outfitters staff report no financial relationships:

  • Marlon (Tony) Graham, MD (peer reviewer)
  • Kashemi D. Rorie, PhD (planning committee)
  • Meghann Taft-Lockard (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Available as a webcast with resources or video only

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.


NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-066-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).



Achieving Optimal Outcomes in Patients with Narcolepsy
Event Date: 06/13/2022